Biotech Growth Rate outperforming classical pharmaceuticals

From ScenarioThinking
Revision as of 13:06, 2 December 2005 by Daniel (talk | contribs) (→‎Experts:)
Jump to navigation Jump to search

Description:

Over the last years, the growth rate of biotech industry has by far outperformed the one of the classical pharma industry. This has not had a positive impact on the profitability of biotech as such – profitability of most classical pharma majors is still higher than the one of most biotech companies – but it has shown in the development of stock prices. Biotechnology stocks have outperformed the ones of classical pharma majors thanks to the hope for future profits.

Enablers:

• Hope for good profit margins
• Hope for huge ROE
• Potential for spectacular breakthroughs in Research.

Inhibitors:

• Increase (instead of decrease) of R&D cost in biotechnology
• Decrease in R&D costs for classical drugs
• Entry barriers getting lower because of increased availability of fundamental research
• Drug Approval regulations getting stricter
• Insecurity regarding the development of legal frameworks
• Price Pressure due to exploding healthcare cost

Paradigms:

• Investors look elsewhere

Experts:

The Future of Biotechnology for Medical Applications in 2005, Growth/Development Issues

Timing:

Web Resources:

See our Research regarding Growth and Development issues